Related Experiment Video
Updated: Jan 6, 2026
09:17
Optimizing Extracellular Vesicle Delivery Using a Core-Sheath 3D-Bioprinted Scaffold for Chronic Wound Management
Published on: February 28, 2025
762
Exosome Therapy for Chronic Wound Healing
Lucas Basamage1, Hee Jin Ahn2, Ho-Sung Choi3
1From Synergie Clinic, Campo Grande, Brazil.
Plastic and Reconstructive Surgery. Global Open
|October 6, 2025
Summary
Exosome therapy promotes healing in chronic lower-extremity ulcers by improving blood flow and reducing inflammation. This cell-free approach demonstrated significant wound closure and was well-tolerated in a small case series.
Area of Science:
- Regenerative Medicine
- Wound Healing
- Vascular Biology
Background:
- Chronic lower-extremity ulcers present significant challenges due to impaired vascularity, inflammation, and extracellular matrix dysfunction.
- Exosome therapy offers a cell-free regenerative approach, potentially addressing these deficits via proangiogenic and immunomodulatory cargo.
- This study evaluates the clinical application of exosome therapy in refractory chronic ulcers.
Purpose of the Study:
- To assess the clinical efficacy and safety of adipose-derived stem-cell exosomes in treating chronic lower-extremity ulcers.
- To evaluate the impact of exosome therapy on wound healing, vascularity, and perfusion.
- To determine the tolerability and potential adverse events associated with exosome application.
Main Methods:
- A case series involving four adult patients with chronic ulcers refractory to conventional treatments.
- Monthly topical application of adipose-derived stem-cell exosomes (Exo-HL) at a concentration of 1 × 10^12 particles/mL.
- Regular wound assessment via photography, measurement, and Doppler ultrasonography to quantify vascular parameters (arterial resistive index, venous reflux time).
Main Results:
- Median baseline ulcer area was 12.4 cm², with three out of four ulcers achieving complete closure within a median of 94 days.
- Significant improvements in vascularity were observed, with mean arterial resistive index decreasing from 0.93 to 0.77 and venous reflux time reducing from 2.8 to 1.4 seconds.
- Exosome therapy was well-tolerated, with no reported adverse events or wound infections.
Conclusions:
- Topical exosome therapy demonstrated potential for rapid granulation, improved perfusion, and durable closure of refractory chronic ulcers.
- The findings suggest exosome therapy is a promising, well-tolerated treatment option for chronic wound healing.
- Further controlled trials are warranted to confirm efficacy and optimize exosome therapy protocols for chronic ulcer management.
Related Concept Videos
01:19Clinical Applications of Epidermal Stem Cells
3.2K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.2K
01:36Overview of Exosomes
3.4K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
3.4K